These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16837726

  • 1. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
    Stoute JA, Heppner DG, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR.
    Am J Trop Med Hyg; 2006 Jul; 75(1):166-70. PubMed ID: 16837726
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
    Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL.
    Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
    [Abstract] [Full Text] [Related]

  • 3. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG.
    Vaccine; 2007 May 22; 25(21):4203-12. PubMed ID: 17442466
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG, MSP-1 Malaria Vaccine Working Group.
    Vaccine; 2007 Jan 02; 25(1):176-84. PubMed ID: 16388879
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, Kester KE, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG.
    Am J Trop Med Hyg; 2004 May 02; 70(5):499-509. PubMed ID: 15155981
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ.
    Vaccine; 2005 Jul 14; 23(32):4148-57. PubMed ID: 15964483
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG, RTS,S Vaccine Evaluation Group.
    J Infect Dis; 2009 Aug 01; 200(3):337-46. PubMed ID: 19569965
    [Abstract] [Full Text] [Related]

  • 8. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL.
    Vaccine; 2004 Apr 16; 22(13-14):1592-603. PubMed ID: 15068840
    [Abstract] [Full Text] [Related]

  • 9. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, Schwenk RJ, Krzych U, Holland CA, Richmond G, Dowler MG, Williams J, Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie MA, Ballou WR, Cohen J, Heppner DG, RTS,S Malaria Vaccine Evaluation Group.
    Vaccine; 2008 Apr 24; 26(18):2191-202. PubMed ID: 18387719
    [Abstract] [Full Text] [Related]

  • 10. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
    Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, Guinovart C, Leach A, Milman J, Macete E, Espasa M, Ofori-Anyinam O, Thonnard J, Corachan S, Dubois MC, Lievens M, Dubovsky F, Ballou WR, Cohen J, Alonso PL.
    Vaccine; 2008 Jan 10; 26(2):174-84. PubMed ID: 18069097
    [Abstract] [Full Text] [Related]

  • 11. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS, Gettayacamin M, Leitner WW, Lyon JA, Stewart VA, Marit G, Pichyangkul S, Gosi P, Tongtawe P, Kester KE, Holland CA, Kolodny N, Cohen J, Voss G, Ballou WR, Heppner DG.
    Vaccine; 2006 May 08; 24(19):4167-78. PubMed ID: 16574282
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
    Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, Milman J, Guinovart C, Mandomando I, López-Púa Y, Lievens M, Owusu-Ofori A, Dubois MC, Cahill CP, Koutsoukos M, Sillman M, Thompson R, Dubovsky F, Ballou WR, Cohen J, Alonso PL.
    Trials; 2007 Mar 26; 8():11. PubMed ID: 17386091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
    Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG, MSP-1 Working Group.
    Vaccine; 2006 Apr 05; 24(15):3009-17. PubMed ID: 16356603
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, Kester KE, Cummings JF, Burge JR, Voss G, Delchambre M, Garçon N, Tang DB, Cohen JD, Heppner DG.
    Vaccine; 2006 Oct 30; 24(42-43):6483-92. PubMed ID: 16904798
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
    Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, Lievens M, Bassat Q, Lafuente S, Macete E, Vekemans J, Guinovart C, Sigaúque B, Sillman M, Milman J, Dubois MC, Demoitié MA, Thonnard J, Menéndez C, Ballou WR, Cohen J, Alonso PL.
    J Infect Dis; 2009 Aug 01; 200(3):329-36. PubMed ID: 19569964
    [Abstract] [Full Text] [Related]

  • 18. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE, Gray Heppner D, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J, RTS,S/TRAP Group.
    Vaccine; 2014 Nov 20; 32(49):6683-91. PubMed ID: 24950358
    [Abstract] [Full Text] [Related]

  • 19. The development of the RTS,S malaria vaccine candidate: challenges and lessons.
    Ballou WR.
    Parasite Immunol; 2009 Sep 20; 31(9):492-500. PubMed ID: 19691554
    [Abstract] [Full Text] [Related]

  • 20. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL.
    Vaccine; 2011 Aug 11; 29(35):6059-67. PubMed ID: 21443960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.